For Clinicians
Biological age offers a measurable endpoint on a timescale that fits a study. It is not a diagnosis or a substitute for clinical judgement; it is an objective measure of whether the trajectory moved.
01 — The clinical gap
Conventional care detects decline once symptoms or established markers appear. It says far less about whether an otherwise healthy person is ageing well.
Longevity interventions are delivered years before the outcomes they are meant to change. Without a study-feasible endpoint, a clinician has no practical way to demonstrate that a protocol changed the trajectory.
Biological age turns that clinical question into a measurable research question.
02 — Who this is for
Restructured hospitals · polyclinics
Focus: Preventive care, early detection, and participant stratification
Specialist practices · longevity medicine
Focus: Demonstrating that what you deliver works
03 — What we run
Longitudinal tracking is designed from enrolment. Clinicians receive interpretable outputs, not a raw-data handoff.
Protocol, endpoints, participant criteria, sample size, and consent and ethics documentation prepared for institutional review. No study infrastructure to build and no prior research experience required.
Your team collects. Logistics, preparation, quality control, and sequencing are handled after that — without a lab build-out, bioinformatics hire, or vendor management.
EpiClock runs 12 validated epigenetic clocks across 8 dimensions, scored consistently across participants and visits. Measurement is independent of clinical assessment, removing ascertainment bias.
Change from baseline is compared against 16 harmonised public studies and delivered as interpretable, publication-ready outputs with co-authorship.
04 — The panel
Rate of ageing, accumulated damage, mortality-associated phenotype, and mitotic history can diverge within the same participant. In an intervention study, that divergence may be the most informative result.
The current panel measures eight dimensions from one methylation sample. Additional modalities are on the roadmap; we will tell you what is available now and what is not.
Chronological
Phenotypic
Pace of ageing
Causal
Damage
Adaptation
Mitotic
Telomere
| Dimension | What it measures | Clocks |
|---|---|---|
| Chronological | Calendar-age estimate | Horvath · Hannum |
| Phenotypic | Morbidity and mortality risk | PhenoAge · GrimAge · PCPhenoAge · PCGrimAge |
| Pace of ageing | Rate of ageing per year | DunedinPACE |
| Causal | Causal chronological signal | CausAge |
| Damage | Accumulated molecular damage | DamAge |
| Adaptation | Protective adaptation | AdaptAge |
| Mitotic | Stem-cell division count | epiTOC2 |
| Telomere | DNA-methylation telomere length | DNAmTL |
05 — Partnership
From your site:
participants, a clinical protocol, and capacity to collect samples.
From BioAge Connect:
documentation, logistics, processing, measurement, data management, and analysis.
Not from BioAge Connect:
clinical delivery or clinical decisions. Those remain entirely yours.
Data ownership and IP attribution are defined at the outset. Processing aligns with PDPA and IRB requirements. Explicit do-not-use policies cover insurance underwriting and employment decisions. Participants consent to defined uses, and results are not returned as clinical or diagnostic findings.
First study sites
No protocol change and no intervention arm — just baseline measurement across an existing population. It is a low-commitment way to establish whether a larger study is worth running. Early partners help shape the measurement panel and study design.